Yatharth Hospital & Trauma Care Services Limited moves to reshape its capital structure

The 2023 IPO capex allocation was Rs 132.61 Crores, but the current unspent balance cannot be established from the reported extract. The allocation comprised:

• Rs 25.64 Crores for capex at the company’s Noida and Greater Noida hospitals, corresponding to the Noida Extension-side facilities referenced in the IPO plan.
• Rs 106.97 Crores for capex at the subsidiaries’ hospitals, including the Orchha facility. ^[1]

The latest monitoring disclosure cited in the available material is for the December 2024 QIP, not the 2023 IPO; it states that the QIP proceeds were fully utilized, but that does not establish the status of the IPO proceeds. ^[2] A March 2026 IPO monitoring report is listed, but its detailed utilization figures are not reproduced. ^[3]

Therefore, the original IPO capex pool was Rs 132.61 Crores, while the amount remaining unspent is not quantifiable from the cited disclosure—not safely assumed to be zero. The key diligence point ahead of any new fundraising is to obtain the latest IPO monitoring-agency reconciliation showing actual spend against the Rs 25.64 Crores and Rs 106.97 Crores commitments.

The proposed fundraising is financially consistent with the scale of the bed-expansion programme, but the board filing does not yet establish that the 5,000-bed target itself requires external capital. It signals a change from management’s earlier position that internal accruals and available debt capacity could fund the plan.

Why the fundraise makes sense financially

The existing operating base is generating cash, but not enough on the FY26 consolidated numbers to fund the reported investment pace internally. The shortfall was also visible in FY25: operating cash flow was Rs 149.60 Crores ^[6] against Rs 310.83 Crores of capex ^[7], implying only 48.13% coverage and a derived Rs 161.23 Crores OCF-minus-capex gap. FY26 net cash flow was negative Rs 139.98 Crores ^[9], despite operating cash generation.

The expansion economics are sizeable. Management quoted approximately Rs 75 lakh of capex per bed for the Greater Noida and Noida Extension brownfield projects, excluding land ^[5]. Separately, the 250-bed Gurugram asset involved Rs 100 Crores of acquisition consideration and a further Rs 100 Crores for completion and equipment, with operations targeted for Q1 FY28 ^[10]. These projects are not equivalent to the entire 5,000-bed gap, but they illustrate why timing can exceed internally generated cash.

What has changed

In the Q4 FY26 earnings call, management said the company had a good cash position, room for additional debt and expected higher internal accruals because of high cash conversion; it specifically said there was no plan to raise funds for the 5,000-bed capacity objective ^[5]. The September board notice therefore suggests one of three developments: faster expansion than previously envisaged, a broader acquisition or growth pipeline, or a desire to preserve liquidity while funding the existing rollout. The filing does not identify which of these is driving the review.

The cash-flow comparison should not be read as a steady-state ceiling. Consolidated operating cash flow includes newer facilities that are still ramping, while unit-level cash generation from mature versus recently added hospitals is not separately disclosed. Management’s stated expectation of higher internal accruals is therefore a forward-looking view, not current-period evidence ^[5].

Analytical conclusion: at the current FY26 cash-conversion level, external funding would help bridge the timing mismatch between the 5,000-bed ambition and the cash generated by operations. However, the board announcement is too preliminary to determine whether the eventual raise is for the remaining bed additions, acquisitions beyond the stated plan, or balance-sheet flexibility.

Yatharth is one of the least levered companies in this peer set. Its latest consolidated gross debt-to-equity ratio is 0.14x and net debt-to-equity is only 0.02x in Q1 FY27, compared with 0.24–0.68x gross debt-to-equity for most peers; only Park Medi World has a lower gross ratio and a net-cash position. ^{[11] [12] [13] [14]}

Leverage snapshot

The comparison is directionally strong but not perfectly like-for-like: Kovai and Park’s latest figures are Q4 FY26, while the other companies’ latest figures are Q1 FY27; Kovai is also reported on a standalone basis.

Company read-through

Yatharth

Yatharth’s debt burden has increased alongside its expansion programme: consolidated debt-to-equity moved from 0.01x in Q2/Q3 FY26 to 0.14x in Q4 FY26 and remained at 0.14x in Q1 FY27. ^[11] Its balance sheet nevertheless remained close to net-cash neutral, with Rs 253.33 Cr of total debt against Rs 221.10 Cr of cash and equivalents in the latest period. ^{[15] [35]}

The company also raised Rs 625 Cr through a QIP in December 2024, increasing paid-up equity share capital from Rs 85.85 Cr to Rs 96.35 Cr. ^[36] It subsequently announced a Gurugram facility involving Rs 100 Cr of acquisition consideration and approximately Rs 100 Cr of additional capex. ^[37] The evidence therefore points to an expansion model supported substantially by equity capital and internal liquidity rather than by high balance-sheet leverage.

Jupiter Life Line

Jupiter is materially more levered than Yatharth, at 0.33x gross and 0.29x net debt-to-equity, with Rs 453.77 Cr of consolidated net debt. ^{[17] [18] [20]} This is consistent with its recent debt-funded expansion: borrowings undertaken for expansion projects increased finance costs by 55.5% YoY in Q1 FY27, while the newly commissioned Dombivli hospital incurred an initial ramp-up loss. ^[38]

HCG

HCG has the highest gross leverage in the group at 0.68x, although its net ratio is lower at 0.28x because of Rs 536.05 Cr of cash. ^{[21] [22] [39]} HCG’s capital cycle has been significantly more debt-intensive: total debt rose from Rs 1,274.4 Cr at March 2024 to Rs 1,837.2 Cr at March 2025 and approximately Rs 1,849 Cr at September 2025, alongside acquisitions and greenfield/brownfield capex. ^[40] Its planned rights issue was expected to fund the second tranche of the MG Hospital acquisition, indicating a more leveraged acquisition-and-capex phase than Yatharth’s current profile. ^[40]

Kovai Medical Center

Kovai’s 0.28x gross and 0.23x net debt-to-equity are above Yatharth’s, with Rs 305.56 Cr of net debt. ^{[25] [26] [28]} Its latest interest coverage was strong at 20.96x, suggesting that the higher leverage was not translating into immediate interest-servicing stress. ^[41] A directly comparable recent fundraising or expansion event is not reported for Kovai in the cited material, so it is best treated as a balance-sheet benchmark rather than a confirmed cycle comparator.

Park Medi World

Park is the closest balance-sheet comparator, with 0.11x gross debt-to-equity and net cash of Rs 8.95 Cr on a consolidated basis. ^{[13] [30]} Its leverage is marginally lower than Yatharth’s, although the latest available figure is Q4 FY26 rather than Q1 FY27. A directly comparable recent fundraising or expansion event is not reported for Park in the cited material.

Artemis Medicare

Artemis has moderate leverage at 0.24x gross and 0.21x net debt-to-equity, with Rs 193.45 Cr of net debt. ^{[31] [32] [34]} That places it between Yatharth and the more indebted Jupiter, HCG and Kovai cohorts. A directly comparable recent fundraising or expansion event is not reported for Artemis in the cited material.

What matters for the consolidation cycle

Yatharth’s principal distinction is balance-sheet capacity: its net debt-to-equity of 0.02x is roughly one-tenth of Jupiter’s 0.29x and HCG’s 0.28x, while its latest consolidated interest coverage remained 14.57x, versus 6.99x for Jupiter and 3.37x for HCG. ^{[12] [42] [43] [44]}

The trade-off is that Yatharth’s debt has already stepped up from a near-zero base as acquisitions and new facilities have progressed. Thus, its current leverage is conservative relative to peers that have funded expansion more aggressively, but the durability of that advantage will depend on whether the planned bed additions are funded through operating cash flow and equity or through a larger debt drawdown.